Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May;11(5):694–709. doi: 10.21037/tau-22-312

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2022 Translational Andrology and Urology. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

Survival time based on metastatic site and age category. (A) Survival curves revealed the impact of different metastatic sites on survival time; patients with lung metastasis only had better PFS than those with bone metastasis only. (B) Patients with a single metastatic organ had a longer PFS than those with multiple metastatic organs. (C) Patients with 2 metastatic organs had better PFS than patients with 3 or more metastatic organs. (D) There was no significant difference in survival time between patients aged ≥65 and <65 years. PFS, progression-free survival.